Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Featured trial
Weekly Basal Insulin - Allowing More Flexibility With Treating Type 1 Diabetes. (In the Greater Seattle Area.)

week, the other half will take Insulin Degludec (Tresiba) administered by insulin pen. All participants would switch to Insulin Aspart (Novolog) administered by insulin pen.

sugars
Accepts healthy volunteers
hemoglobin a1c
insulin
  • 36 views
  • 08 Oct, 2021
  • 1 location
Featured trial
Do You Take Two Insulins to Treat Your Type 2 Diabetes?

: Basal insulin: Lantus or Basaglar (Glargine) Bolus insulin: Humalog (Lispro), Novolog (Aspart), or Apidra (Glulisine). With or without up to 3 of the following:

lantus
continuous glucose monitoring
sugars
metformin
hemoglobin a1c
  • 24 views
  • 22 Oct, 2021
  • 1 location
Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients

The aim of this study is to compare the pharmacokinetic (PK) profile of diluted insulin aspart (U25) with undiluted insulin aspart (U100) in school-aged children and adolescents with type 1

  • 6 views
  • 06 Jun, 2022
  • 1 location
Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes (MIRE)

insulins mimicking the physiological secretion more closely has led to ultra-fast insulins (fast aspart), allowing for postprandial hyperglycaemia to be better controlled. In Type 1 diabetics treated with

  • 0 views
  • 12 May, 2022
  • 1 location
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with

  • 0 views
  • 05 Apr, 2022
  • 58 locations
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

In this prospective, randomized, open-label, parallel group trial, the safety and efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with basal insulin once or

  • 0 views
  • 23 Jul, 2021
  • 1 location
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

This global study (US, Canada, and Europe) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection

glycosylated hemoglobin
diabetes
hemoglobin a1c
insulin
  • 0 views
  • 04 Oct, 2022
  • 7 locations
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers: A Single-Center Randomized, Double-blinded, Two-Treatment, Two-period, Two-sequence Crossover, Hyperinsulinemia-Euglycemic Clamp

This study is a randomized, double-blinded, two-treatment, two-period, two-sequence crossover pivotal Biosimilar study. The purpose of this study is to establish pharmacokinetic (PK) and pharmacodynamics (PD) biosimilarity of proposed biosimilar I004 and the US-approved NovoLog.

Accepts healthy volunteers
  • 0 views
  • 17 Oct, 2022
Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart or

  • 17 views
  • 07 Oct, 2022
  • 22 locations
Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

There is a fundamental gap in understanding the maternal and neonatal effects of antenatal corticosteroid (ACS) administration in women with threatened preterm birth (PTB) who have diabetes. Since the initial discovery of ACS for neonatal benefit in 1972, more than 40 randomized controlled trials have been performed evaluating its efficacy. …

  • 0 views
  • 27 Apr, 2022
  • 1 location